Patent for covid19 virus exists

Name
Email
Subject
Comment *
File	Select/drop/paste files here
Password	(Randomized for file and post deletion; you may also set your own.)
Archive	Archive [500 char limit]
* = required field	[▶ Show post options & limits] Confused? See the FAQ.

Embed	(replaces files and can be used instead)
Voice recorder	Show voice recorder (the Stop button will be clickable 5 seconds after you press Record)
Options	Do not bump (you can also write sage in the email field)
Allowed file types:jpg, jpeg, gif, png, webm, mp4, pdf Max filesize is 16 MB. Max image dimensions are 15000 x 15000. You may upload 5 per post.

Patent for covid19 virus exists Anonymous 04/21/20 (Tue) 22:46:41 d6020f No.8877678

https://rat.com/index.php/9-featured/covid-19-patent-application-approved-november-2019

COVID-19 Patent Application Approved November 2019

Rat.com Editorial

A patent application for a vaccine to prevent the Novel Coronavirus (SARS-CoV-2) spreading has been in existence since just after the last viral pandemic, Middle East Respiratory Syndrome (MERS), was abated, in 2015,m Rat.com has learned. Further, the patent was granted in November last year. The patent was granted to the Pirbright Institute in Surrey, U.K.

Patent No. EP3172319 B1 was filed on July 23, 2017 and the patent was granted on November 11, 2019 according to a European patent filing. The patent application covers SARS-CoV and a similar strain of the virus known as Human Coronavirus or HCoV-HKU1. The patent application specifies that the HCoV-HKU1 virus strain “has no name yet”.

The existence of a possible vaccination for COVID-19 calls into question much of the panic that has been the subject of the last two months’ mainstream media reports. Monday, a journalist was overheard on a hot mic in the White House Press Room saying that members of the press “had all been vaccinated [against SARS-CoV-2]”.

An academic paper from 2007 supports the notion that there is a possible vaccine already developed for the SARS-CoV-2 virus, which it describes as a form of HCoV-HKU1. The paper also details a brief history of how COVID-19 came into being and came to be understood extremely well by scientists, including the narrative of how the infection stemmed from a bat:

By infecting healthy volunteers, researchers learned that infection with HCoV-229E or HCoV-OC43 results in a common cold (7, 8, 29), and since then, HCoVs have been considered to be relatively harmless respiratory pathogens. This image was roughly disturbed when severe acute respiratory syndrome (SARS)-CoV was introduced into the human population in the winter of 2002 to 2003 in China. SARS-CoV causes a severe respiratory illness with high morbidity and mortality (16, 40). The virus originated from a wild-animal reservoir, most likely bats (43, 46), and was transmitted to humans via infected civet cats. The epidemic was halted in 2003 by a highly effective global public health response, and SARS-CoV is not currently circulating in humans. However, the SARS outbreak brought coronaviruses back into the limelight, and a renewed interest in this virus family resulted in the identification of two more human coronaviruses. We discovered HCoV-NL63, a novel member of group I, in a child with bronchiolitis in The Netherlands (74). HCoV-HKU1, a novel group II virus from an adult with chronic pulmonary disease in Hong Kong, was described in 2005 (81). An animal model is currently lacking for these previously unknown viruses. Nevertheless, since the discovery of HCoV-NL63 and HCoV-HKU1, much knowledge about these viruses has been gained. Several groups have studied their worldwide spread, association with human disease, replication characteristics, genome organization, and genetic diversity.

____________________________

Disclaimer: this post and the subject matter and contents thereof - text, media, or otherwise - do not necessarily reflect the views of the 8kun administration.

Pirbright found to own second patent for Cov granted Nov 2018 Rat.com 04/22/20 (Wed) 04:15:23 a7703d No.8881219

Earlier today, Rat.com reported that a patent existed for possible vaccination of SARS-CoV-2 filed under the European Patent Office and granted on Nov. 11, 2019. Rat.com has since learned that a US equivalent patent was granted a year earlier on November 20, 2018 to the same patent holder, Pirbright Institute in Surrey, UK.

The British National Health Service and Pirbright insisted earlier in the year that any patents belonging to Patent to treat Coronavirus apply to a weaker strain of SARS-CoV-2. Rat.com is preparing a list of question for the Pirbright Institute to this effect, since confusion hangs over the definitions.

How Patents Work

Patent applications tend to cover broad-based concepts which are treated with specific solutions. For example, in the case of the Pirbright patents, vaccination and thereapeutic treatments target nonstructural proteins 10, 14, 15 and 16 specifically. These same non structural proteins are the basis of the mutation of the SARS-Cov`-2 virus. In this light, a reading of the Pirbright patents would appear to adequately protect vaccinations and therapeutics that might be useful in treating COVID-19.

Indeed, the institute says as much by its own admission. “Pirbright is one of few facilities in the world that has the expertise in animal immunology and the state-of-the-art virology facilities required to undertake this type of work” the Institute maintains on its website. Pirbright, which received a 5 million pound grant from the Bill and Melinda Gates Foundation, goes on to list its current activities with respect to actively sourcing treatments and vaccines for COVID-19:

“The Pirbright Institute is joining in the global battle to help control COVID-19 by using its unique expertise and facilities to support the development of vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the current pandemic.

Working in collaboration with researchers at the University of Oxford and Public Health England, a team of scientists at Pirbright will begin testing new vaccines for their ability to induce protective antibodies against SARS-CoV-2. The vaccines will include the chimpanzee adenovirus vaccine vector (ChAdOx1) which is soon to enter human phase I clinical trials and has been used to create vaccines for diseases like Ebola, Middle Eastern respiratory syndrome (MERS) and flu.

The vaccine candidates developed at Oxford will contain the spike protein from SARS-CoV-2, the protein against which protective antibodies are generated in infected patients. Pirbright scientists will measure the level of antibodies produced after vaccination of pigs and assess whether the antibodies can block SARS-CoV-2 from infecting cells, thereby preventing infection. Importantly, the pig immune system shares significant similarities to that of humans, so a good response to a vaccine in pigs will help to predict the success of vaccines for human use. Researchers will also test the safety of the new vaccines and monitor whether any adverse effects are observed in the pigs.

This work will inform the development of vaccines that are both effective and safe for humans.”

Cont at https://rat.com/index.php/9-featured/32-pirbright-owns-us-coronavirus-patent-granted-nov-20-2018

Disclaimer: this post and the subject matter and contents thereof - text, media, or otherwise - do not necessarily reflect the views of the 8kun administration.